Patent intelligence · US
US 6646120
Dextran derivatives, preparation and medicinal applications
Dextran derivatives, preparation and medicinal applications
Patent details — US 6646120
- Jurisdiction
- US
- Status
- expired
- Grant date
- Nov 11, 2003
- Expiration
- Nov 6, 2023
- Applicant
- BIODEX
- Claims
- 14
- CPC classes
- A61P, A61P43/00, A61P7/02
Quick answer
US 6646120 (Dextran derivatives, preparation and medicinal applications) is held by BIODEX. Status: expired. Granted Nov 11, 2003. Expires Nov 6, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIODEX
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61P, A61P43/00, A61P7/02
More from BIODEX
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 6646120?
US 6646120 (Dextran derivatives, preparation and medicinal applications) is held by BIODEX. Status: expired. Granted Nov 11, 2003. Expires Nov 6, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6646120?
BIODEX is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 6646120 expire?
Our index shows an expiration date of Nov 6, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.